key: cord-0746770-fifqb5dj
authors: Davogustto, Giovanni E.; Clark, Daniel E.; Hardison, Edward; Yanis, Ahmad H.; Lowery, Brandon D.; Halasa, Natasha B.; Wells, Quinn S.
title: Characteristics Associated With Multisystem Inflammatory Syndrome Among Adults With SARS-CoV-2 Infection
date: 2021-05-19
journal: JAMA Netw Open
DOI: 10.1001/jamanetworkopen.2021.10323
sha: 17d702e4399a6d9863027b4f591ee8f9fdab0d1c
doc_id: 746770
cord_uid: fifqb5dj

This cohort study describes the clinical characteristics and outcomes of patients with multisystem inflammatory syndrome among adults with laboratory-confirmed SARS-CoV-2 infection at a single US tertiary care medical center.

The overview of patient selection is depicted in eFigure 1. Adults ≥ 21 years-old at risk of multisystem inflammatory syndrome associated with SARS-CoV-2 infection (MIS-A) were identified as those hospitalized surrounding SARS-CoV-2 testing based on diagnostic method as follows: (eFigure 2) 1) RT-PCR group:

a. Positive SARS-CoV-2 RT-PCR nasopharyngeal swab followed. b. Hospital admission ≥ 14 days and ≤ 84 days (12 weeks) from initial positive PCR test. 2) Serology group: a. Positive SARS-CoV-2 IgG. b. Hospital admission within 15 days before or after positive IgG test.

In the RT-PCR group, a 14-day "blanking period" was implemented to avoid contamination from admissions driven by acute COVID-19 rather than MIS-A. We selected 14 days, because it has been previously suggested that a substantial proportion of MIS-C patients were infected with SARS-CoV-2 at least 1-2 weeks before MIS-C onset. 3 Patients admitted >84 days following positive SARS-CoV-2 RT-PCR were excluded. All others admitted were included in the Acute COVID-19 admission group used for comparison. Although the CDC working definition of MIS-A, defines evidence of prior SARS-CoV-2 infection as any positive test within 12 weeks of symptoms, and does not stipulate a 14-day blanking period from SARS-CoV-2 RT-PCR, we modified this criterium due to the limitations of our retrospective study and potential overlap with acute COVID-19.

For serology, a 15-day window was selected as what the authors thought represented reasonable period for a serology result to be obtained in the onset of MIS-A or to return following potential discharge following MIS-A admission and not be attributable to another systemic illness.

Then, charts of individuals at risk of MIS-A were manually reviewed by one of three physicians in the team (D.E.C., G.E.D., E.H.) to identify charts to discuss in an adjudication group. Patients were excluded during screening if recorded admissions were: 1) Procedural: Delivery, c-section, and other elective procedures.

2) Well-supported alternative diagnosis: For example, sepsis with positive bacterial cultures. 3) Not meeting at least 4 of the 5 MIS-A criteria from the CDC definition. 4 4) Lack of recovery and progression from COVID-19 initial presentation.

All remaining cases at risk for MIS-A were then presented in a three-physician decision group (comprised by D.E.C., G.E.D., E.H.) and adjudicated as case or excluded. Disagreements were resolved by consensus.

Cases reviewed in full were adjudicated as MIS-A if the review team agreed that the cases met all 5 MIS-A criteria from CDC's case definition and no alternative explanation of the presentation was plausible.

Organ-system involvement was adjudicated on the basis of symptoms, clinical findings, and laboratory measurements, similarly to previously described 3 and are presented in eTable 2.

Demographics, BMI, and chronic comorbidities for all participants were extracted from the EHR. Definitions used to identify comorbidities are provided in eTable 1.

Additional data collected of MIS-A cases included clinical presentation, vital signs on admission, laboratory parameters and microbiologic data obtained during admission, organ system involvement as described above, findings on cardiovascular diagnostic studies, therapies, and survival. Data were obtained from medical records and collected in a Vanderbilt's Research Electronic Data Capture (REDCap) by a member of the research team (D.E.C., G.E.D, E.H., A.Y.).

Data are presented as median and interquartile range for continuous variables, and counts and percentages for categorical variables unless otherwise specified. Missing data were not imputed. Continuous variables were compared using Mann-Whitney U test, and categorical variables compared with Fisher's exact test. Tests were twotailed. A p-value <0.05 was considered significant. Data analyses were performed and graphs created using R software, version 4.0.2 (R foundation for Statistical Computing, Vienna, Austria).

Presence of ANY of the following codes throughout the record: ICD9: 401", "401.*", "402", "402.*", "403", "403.*", "404", "404.*", "405", "405.*" ICD10: "I10", "I10.*", "I11", "I11. Presence of at least one code AND one medication from the list below, AND one BNP (with value > 100 pg/ml) ICD9: 425, 425.*, 428, 428.* ICD10: I42, I42.*, I50, I50.* Medications: "furosemide", "lasix", "bumetanide", "bumex", "torsemide", "demadex", "ethacrynic acid", "edecrin", "metolazone", "zaroxolyn" "roflumilast", "daliresp", "tiotropium", "spiriva", "ipratropium", "atrovent", "theophylline", "slobid", "slo-phyllin", "theo-dur", "theo 24", "theo24", "theo-24", "uniphyl", "salmeterol", "serevent", "formoterol", "foradil", "albuterol + ipratropium", "albuterol / ipratropium", "ipratropium bromide / albuterol sulfate", "ipratropium bromide with albuterol sulfate", "combivent", "duoneb", "albuterol", "proventil", "proair", "ventolin", "fluticasone", "salmeterol", "advair", "budesonide/formoterol", "budesonide / formoterol", "budesonide -formoterol", "budesonide-formoterol", "mometasone/formoterol", "mometasone / formoterol", "dulera", "beclomethaosne", "qvar", "budesonide", "pulmicort", "fluticasone", "flovent", "mometasone", "asmanex" CKD Presence of ANY eGFR < 60 ml/min throughout the record CAD: Coronary artery disease, COPD: Chronic obstructive pulmonary disease, CKD: Chronic kidney disease. 

Secondary use of clinical data: the Vanderbilt approach

Race/Ethnicity Among Children With COVID-19-Associated Multisystem Inflammatory Syndrome

Multisystem Inflammatory Syndrome in U.S. Children and Adolescents

Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection -United Kingdom and United States

Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Section 2: AKI Definition

Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients